It will buy immunology company Telavant Holdings from Roivant Sciences and Pfizer.
Swiss pharmaceutical company Roche said Monday it has agreed to buy immunology company Telavant Holdings from Roivant Sciences and Pfizer in a $7.1 billion deal.Telavant, which has a promising drug candidate to treat inflammatory bowel disease, was jointly formed last year by Roivant Sciences and Pfizer . It was created to develop and commercialize the drug, known as RVT-3101, in the U.S. and Japan.
Roche will take on the rights to develop and commercialize it in the U.S. and Japan pending regulatory success. The Swiss company will pay a near-term milestone payment of $150 million on top of the $7.1 billion. Roche said Pfizer owns the remaining 25% stake in Telavant, and that it holds commercialization rights outside the U.S. and Japan. The agreement also includes the option for Roche to collaborate with Pfizer on a next-generation antibody currently in early-stage trials.
Roivant Sciences stock looked to be the big winner from the deal in early trading Monday. Pfizer stock pointed 0.5% higher ahead of the open, while shares in Roche were flat in European trading.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln DealBy Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it...
Read more »
Roche buys Telavant Holdings for $7.1 billionRoche buys Telavant Holdings for $7.1 billion
Read more »
Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant HoldingsSwiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Read more »
Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant HoldingsSwiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Read more »
Chevron, Hess, Roivant, Textainer, Microsoft, Alphabet, and More Stock Market MoversChevron will buy Hess in all-stock deal valued at $53 billion, Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease...
Read more »
Solar Panels and Nuclear EnergySaleem H. Ali is Chair of the Department of Geography and Spatial Sciences and the Blue & Gold Distinguished Professor of Energy and the Environment at the University of Delaware (USA).
Read more »